Improving the Patient's Experience of a Bone Marrow Biopsy - An evidence based approach to service improvement.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-005410-21-GB

Enrollment

Registered

2006-03-24

Start date

2006-04-20

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Procedural pain experienced during bone marrow biopsy

Interventions

Trade Name: Entonox Pharmaceutical Form: Inhalation gas Pharmaceutical form of the placebo: Inhalation gas Route of administration of the placebo: Inhal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients attending the haematology day case unit who are over 18 years of age requiring bone marrow biopsy and who agree to take part in the study. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients who have contraindications to Entonox or Oxygen: Artificial, traumatic or spontaneous pneumothorax Air embolism Decompression sickness Recent underwater dive Severe bullous emphysema Myringoplasty Intestinal obtruction Head injury with impaired consciousness Intoxication Maxillofacial injuries Chronic obstructive pulmonary disease Asthma Wthin first 16 weeks of pregnancy Patients who wish to drive or operate machinery within 12 hours of the procedure In addition, patients who have used Entonox within the last 10 years will also be excluded. This will avoid the possibility of their being unblinded as to the treatment condition to which they have been allocated in the study. Patients who have already participated in this trial and require further biopsies will not be eligible for re-entry into the study.

Design outcomes

Primary

Measure	Time frame
Main Objective: Is the level of pain experienced by patients undergoing a bone marrow biopsy improved by the administration of Entonox?;Secondary Objective: To assess the acceptability of Entonox as a method of pain control in this patient population.; Primary end point(s): when the patient no longer self-administers gas following completion of questionnaire	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026